Humana (HUM) Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HUM shares.
View HUM analyst ratings or view top-rated stocks.

15 brokers have issued 12 month target prices for Humana's shares. Their HUM share price forecasts range from $510.00 to $652.00. On average, they anticipate the company's share price to reach $599.72 in the next twelve months. This suggests a possible upside of 17.7% from the stock's current price.
View analysts price targets for HUM or view top-rated stocks among Wall Street analysts.

Humana's stock was trading at $512.19 at the beginning of 2023. Since then, HUM shares have decreased by 0.5% and is now trading at $509.67.
View the best growth stocks for 2023 here.

Humana saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,520,000 shares, a decrease of 9.0% from the April 30th total of 1,670,000 shares. Based on an average daily trading volume, of 895,600 shares, the short-interest ratio is currently 1.7 days. Approximately 1.2% of the company's shares are short sold.
View Humana's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 26th 2023.
View our HUM earnings forecast.

Humana Inc. (NYSE:HUM) posted its earnings results on Wednesday, April, 26th. The insurance provider reported $9.38 EPS for the quarter, topping the consensus estimate of $9.25 by $0.13. The insurance provider had revenue of $26.74 billion for the quarter, compared to the consensus estimate of $26.40 billion. Humana had a net margin of 3.26% and a trailing twelve-month return on equity of 21.04%. Humana's revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $8.04 earnings per share.
Read the conference call transcript.

Humana declared a quarterly dividend on Thursday, April 20th. Shareholders of record on Friday, June 30th will be paid a dividend of $0.885 per share on Friday, July 28th. This represents a $3.54 annualized dividend and a yield of 0.69%. The ex-dividend date is Thursday, June 29th.
Read our dividend analysis for HUM.

ETFs with the largest weight of Humana (NYSE:HUM) stock in their portfolio include AI Powered Equity ETF (AIEQ), Janus Henderson US Sustainable Equity ETF (SSPX), iShares U.S. Healthcare Providers ETF (IHF), WBI BullBear Quality 3000 ETF (WBIL), Hennessy Stance ESG Large Cap ETF (STNC), FIS Biblically Responsible Risk Managed ETF (PRAY), Alpha Intelligent - Large Cap Value ETF (AILV) and Goldman Sachs Hedge Industry VIP ETF (GVIP).

Humana (NYSE:HUM) pays an annual dividend of $3.54 per share and currently has a dividend yield of 0.69%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 14.38%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HUM will have a dividend payout ratio of 11.06% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HUM.

Humana issued an update on its FY23 earnings guidance on Thursday, June, 1st. The company provided EPS guidance of $28.25 for the period, compared to the consensus EPS estimate of $28.32.

1,597 employees have rated Humana Chief Executive Officer Bruce D. Broussard on Glassdoor.com. Bruce D. Broussard has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Humana investors own include UnitedHealth Group (UNH), NVIDIA (NVDA), Walt Disney (DIS), Visa (V), Mastercard (MA), Alibaba Group (BABA), Boeing (BA), Salesforce (CRM), Johnson & Johnson (JNJ) and JPMorgan Chase & Co. (JPM).

Humana trades on the New York Stock Exchange (NYSE) under the ticker symbol "HUM."

Humana's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.03%), Price T Rowe Associates Inc. MD (6.14%), Wellington Management Group LLP (5.88%), FMR LLC (5.88%), State Street Corp (4.57%) and GQG Partners LLC (1.80%). Insiders that own company stock include Bruce D Broussard, Christopher H Hunter, David A Jr/Ky Jones, David A Jr/Ky Jones, Jorge S Mesquita, Joseph C Ventura, Samir Deshpande, Susan M Diamond, Timothy Alan Wheatley, Timothy S Huval and William Kevin Fleming.
View institutional ownership trends.

Shares of HUM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HUM stock can currently be purchased for approximately $509.67.

Humana (NYSE:HUM) has a market capitalization of $63.68 billion and generates $92.87 billion in revenue each year. The insurance provider earns $2.81 billion in net income (profit) each year or $24.62 on an earnings per share basis.

The company employs 67,100 workers across the globe.

Humana's mailing address is 500 West Main Street, LOUISVILLE KY, 40202. The official website for the company is www.humana.com. The insurance provider can be reached via phone at (502) 580-1000, via email at amysmith@humana.com, or via fax at 502-580-3639.